Our Mission

The National Hemophilia Foundation (NHF) Central Ohio Chapter is dedicated to finding cures for inheritable blood disorders and addressing and preventing the complications of these disorders through research, education, and advocacy enabling people and families to thrive.

News & Announcements

FOR IMMEDIATE RELEASE   

MEDIA CONTACT                                                                            

Ilana Ostrin   

Senior Director of Public Relations and Communications  

iostrin@hemophilia.org

212-328-3769 

Aug. 28, 2022

BioMarin recently shared findings from a phase 3 clinical trial (GENEr8-1) evaluating the presence of vector DNA in patients two years after they received a single dose of valoctocogene roxaparvovec, the company’s investigational hemophilia A gene therapy.

Novo Nordisk recently announced that the U.S.

As investigational hemophilia gene therapies move closer to regulatory authorization, community stakeholders have recognized the acute need for people with hemophilia (PWH) and healthcare professionals (HCPs) to be fully engaged in shared decision making (SDM).

PO Box 147
Richwood, OH 43344

© Central Ohio Chapter of the National Hemophilia Foundation 2022

Crafted by Firespring